Berchuck, A., Pharoah, P., Ramus, S., Gayther, S., Palmieri, R., Pearce, C., … Risch, H. (2011). Association of KRAS SNP rs61764370 with risk of invasive epithelial ovarian cancer: Implications for clinical testing. Gynecologic Oncology, 121(2), S2–S3. https://doi.org/10.1016/j.ygyno.2011.02.028

Berchuck, A., P. Pharoah, S. Ramus, S. Gayther, R. Palmieri, C. Pearce, F. Couch, et al. “Association of KRAS SNP rs61764370 with risk of invasive epithelial ovarian cancer: Implications for clinical testing.” Gynecologic Oncology 121, no. 2 (May 2011): S2–3. https://doi.org/10.1016/j.ygyno.2011.02.028.

Berchuck A, Pharoah P, Ramus S, Gayther S, Palmieri R, Pearce C, et al. Association of KRAS SNP rs61764370 with risk of invasive epithelial ovarian cancer: Implications for clinical testing. Gynecologic Oncology. 2011 May;121(2):S2–3.

Berchuck, A., et al. “Association of KRAS SNP rs61764370 with risk of invasive epithelial ovarian cancer: Implications for clinical testing.” Gynecologic Oncology, vol. 121, no. 2, Elsevier BV, May 2011, pp. S2–3. Crossref, doi:10.1016/j.ygyno.2011.02.028.

Berchuck A, Pharoah P, Ramus S, Gayther S, Palmieri R, Pearce C, Couch F, Antonio A, Goode E, Schildkraut J, Chenevix-Trench G, Sellers T, Risch H. Association of KRAS SNP rs61764370 with risk of invasive epithelial ovarian cancer: Implications for clinical testing. Gynecologic Oncology. Elsevier BV; 2011 May;121(2):S2–S3.